Isatuximab

Crescent Biopharma has appointed Jan Pinkas, Ph.D., as chief scientific officer, bringing over two decades of oncology drug development experience including expertise in antibody-drug conjugates.

The IRAKLIA phase 3 study demonstrated that Sarclisa administered subcutaneously via an on-body injector achieved non-inferior efficacy compared to intravenous infusion, with objective response rates of 71.1% versus 70.5% respectively.

Stem cell transplantation remains a cornerstone treatment for multiple myeloma despite the emergence of CAR T-cell therapy and bispecific antibodies, offering a cost-effective "one and done" approach that has proven efficacy over four decades.

• DARZALEX (daratumumab), Janssen's CD38-targeting monoclonal antibody, has transformed multiple myeloma treatment across all lines of therapy, generating $11.6 billion in worldwide sales in 2024. • The drug's success stems from its versatility in combination regimens, expanded approvals for both newly diagnosed and relapsed/refractory patients, and the introduction of DARZALEX FASPRO, a convenient subcutaneous formulation. • Despite growing competition from emerging therapies like Sanofi's SARCLISA and novel BCMA-targeting agents, DARZALEX maintains market leadership through first-mover advantage and robust clinical efficacy data.

Kangpu Biopharmaceuticals has secured IND approval from China's NMPA for KPG-818, a novel oral molecular glue modulator targeting relapsed/refractory multiple myeloma.